Acer Therapeutics (Acer Therapeutics) 1-Year ROIIC % : 8.29% (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Acer Therapeutics's 1-Year ROIIC % for the quarter that ended in Jun. 2023 was 8.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Acer Therapeutics's 1-Year ROIIC % or its related term are showing as below:

ACER's 1-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -3.52 vs ACER: 8.29

Acer Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for Acer Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics 1-Year ROIIC % Chart

Acer Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

1-Year ROIIC %

Get a 7-Day Free Trial

-16,950.00

-882.74

32,250.00

27.88

62.54

Acer Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
1-Year ROIIC %	Get a 7-Day Free Trial															7.33	40.71	62.54	-33.16	8.29

Competitive Comparison of Acer Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, Acer Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acer Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's 1-Year ROIIC % falls into.

Acer Therapeutics 1-Year ROIIC % Calculation

Acer Therapeutics's 1-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:

1-Year ROIIC %	=	1-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	1-Year Incremental Invested Capital
	=	( -19.785 (Jun. 2023) - -21.811 (Jun. 2022) )	/	( 40.886 (Jun. 2023) - 16.455 (Jun. 2022) )
	=	2.026	/	24.431
	=	8.29%^***

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Acer Therapeutics (OTCPK:ACER) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Acer Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acer Therapeutics (Acer Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » 1-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458

Website

https://www.acertx.com

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Executives

Chris Schelling	director, officer: President and Chief Executive	C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden	officer: Chief Operating Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel	officer: Chief Medical Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul	officer: Chief People Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis	officer: Chief Business Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph	officer: Chief Legal Officer and Secy	C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp	officer: Chief Technology Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin	officer: Chief Opp. and Financial Offr	C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello	director	500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458